OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study-Reference-Cited by-同舟云学术

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

Published:2022-11-03 Issue:2 Volume:270 Page:986-994
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Altamura Claudia^ORCID,Ornello R.^ORCID,Ahmed F.^ORCID,Negro A.^ORCID,Miscio A. M.,Santoro A.,Alpuente A.^ORCID,Russo A.,Silvestro M.,Cevoli S.^ORCID,Brunelli N.^ORCID,Grazzi L.^ORCID,Baraldi C.^ORCID,Guerzoni S.^ORCID,Andreou A. P.^ORCID,Lambru G.^ORCID,Frattale I.,Kamm K.,Ruscheweyh R.^ORCID,Russo M.^ORCID,Torelli P.^ORCID,Filatova E.,Latysheva N.^ORCID,Gryglas-Dworak A.,Straburzynski M.^ORCID,Butera C.,Colombo B.,Filippi M.^ORCID,Pozo-Rosich P.^ORCID,Martelletti P.^ORCID,Sacco S.^ORCID,Vernieri F.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s00415-022-11457-5.pdf

Reference47 articles.

1. Steiner TJ, Stovner LJ, Jensen R et al (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137. https://doi.org/10.1186/s10194-020-01208-0

2. Safiri S, Pourfathi H, Eagan A et al (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163:E293–E309. https://doi.org/10.1097/J.PAIN.0000000000002275

3. Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485–1495. https://doi.org/10.1016/S0140-6736(20)32160-7

4. Wijeratne T, Tang HM, Crewther D, Crewther S (2019) Prevalence of migraine in the elderly: a narrated review. Neuroepidemiology 52:104–110. https://doi.org/10.1159/000494758

5. Dogra S, Dunstan DW, Sugiyama T et al (2022) Active aging and public health: evidence, implications, and opportunities. Annu Rev Public Health 43:439–459. https://doi.org/10.1146/annurev-publhealth

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine;Cephalalgia;2024-09

2. Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management;Nature Reviews Neurology;2024-08-19

3. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study;The Journal of Headache and Pain;2024-02-02

4. Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review;Therapeutics and Clinical Risk Management;2023-11

5. Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study;Toxins;2023-04-15